Barcelona, Spain – July 17, 2026 – Grifols, a global leader in the plasma-derived medicines and biosciences sector, has announced a significant stride in its commitment to expanding treatment options for patients with complex immune system disorders. The company has successfully dosed the first participants in two distinct Phase III clinical trials, SIGMA and XPERT, aimed at securing label expansions for its widely utilized immunoglobulin therapies, Gamunex-C and Xembify. These pivotal studies underscore Grifols’ dedication to innovation and its ongoing investment in enhancing the lives of individuals grappling with immune deficiencies and neurological conditions.
The initiation of these trials marks a crucial phase in Grifols’ comprehensive research and development strategy, focusing on leveraging its deep expertise in immunoglobulin (Ig) therapies to address unmet medical needs. By seeking to extend the approved indications for Gamunex-C and Xembify, Grifols aims to provide healthcare professionals with a broader spectrum of therapeutic choices and offer patients greater flexibility and convenience in managing their conditions.
SIGMA Trial: Enhancing Protection Against Infections in Secondary Immunodeficiency
The SIGMA trial is a cornerstone of Grifols’ efforts to broaden the utility of Gamunex-C, its intravenous immunoglobulin (IVIg) therapy. This study is specifically designed to evaluate the efficacy of Gamunex-C when administered in conjunction with standard medical care for patients diagnosed with Secondary Immunodeficiency (SID). SID is a condition characterized by a weakened immune system, often occurring as a consequence of other underlying diseases or medical treatments.
The trial will primarily focus on individuals with SID stemming from hematological malignancies, including B-cell chronic lymphocytic leukemia, multiple myeloma, and non-Hodgkin lymphoma. These patient populations are particularly vulnerable to infections due to their compromised immune defenses, often exacerbated by their cancer treatments. A key objective of the SIGMA trial is to rigorously demonstrate that the rate of serious bacterial infections (SBIs) in this cohort is significantly reduced, aiming for less than one SBI per participant per year. This target reflects a critical benchmark for assessing the protective capacity of immunoglobulin therapy in preventing life-threatening infections.
The SIGMA trial is structured as an open-label, multi-center, single-arm study, enrolling approximately 50 participants. All participants will have a confirmed diagnosis of hypogammaglobulinaemia and a documented history of the aforementioned blood cancers. The open-label nature of the study allows for clear observation of the treatment’s effects, while the multi-center approach ensures a diverse patient population and broader applicability of the findings. The single-arm design will focus on the outcomes of participants receiving Gamunex-C alongside their standard care.
This trial builds upon the established clinical profile of Gamunex-C, which is already a trusted IVIg therapy for various immune deficiencies. By investigating its role in a specific sub-group of SID patients, Grifols aims to solidify its position as a vital therapeutic agent in mitigating infectious complications associated with these serious conditions.
XPERT Trial: Evaluating Xembify’s Non-Inferiority in CIDP Management
In parallel, the XPERT trial is a critical step in evaluating Xembify, Grifols’ subcutaneous immunoglobulin (SCIg) therapy. This multi-center study will involve approximately 40 patients diagnosed with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP). CIDP is a rare, autoimmune neurological disorder characterized by progressive weakness and sensory loss in the limbs, stemming from damage to the myelin sheath that insulates nerve fibers.
The XPERT trial’s primary objective is to compare the pharmacokinetics (how the body absorbs, distributes, metabolizes, and excretes the drug), safety, and efficacy of Xembify with those of Gamunex-C when used as maintenance therapy for CIDP. This comparative analysis is particularly significant because Gamunex-C already holds an approved indication for CIDP in the United States. The XPERT trial will rigorously assess whether Xembify, administered subcutaneously, demonstrates non-inferiority to the established intravenous treatment for this indication.
The trial is being conducted across approximately 20 sites in both the United States and Europe, ensuring a robust and geographically diverse patient cohort. The development of subcutaneous immunoglobulin therapies like Xembify represents a significant advancement in patient care, offering the potential for more convenient self-administration and reduced treatment burden compared to intravenous infusions. If Xembify proves to be non-inferior to Gamunex-C in CIDP management, it could offer a valuable alternative for patients seeking greater autonomy and flexibility in their treatment regimens.
Chronology of Advancements in Immunoglobulin Therapies
Grifols’ commitment to advancing immunoglobulin therapies is a long-standing one, marked by a continuous pipeline of research and development. The initiation of the SIGMA and XPERT trials is the latest in a series of strategic moves designed to solidify its leadership in this therapeutic area.
- Late 2022: Grifols announced the EXCELL trial, another significant study contributing to its ongoing immunoglobulin research program. While specific details of the EXCELL trial were not elaborated upon in the provided text, its announcement signifies a consistent and strategic investment in exploring new frontiers for Ig therapies.
- November 2024: In a separate but related development, Grifols’ subsidiary, GigaGen, commenced a Phase I dose escalation trial for GIGA-2339. This recombinant polyclonal drug candidate is being investigated for its potential in treating hepatitis B virus infection, showcasing Grifols’ broader commitment to leveraging biological innovation beyond traditional plasma-derived products.
- July 2026 (Current Announcement): The dosing of the first patients in the SIGMA and XPERT trials marks a critical milestone, moving these key studies into their active phases. This development is poised to generate significant data that could lead to important label expansions for Gamunex-C and Xembify.
This chronological overview highlights Grifols’ sustained and multi-faceted approach to research, encompassing both established plasma-derived therapies and novel recombinant approaches. The company’s strategic investments are geared towards addressing diverse patient needs and expanding the therapeutic landscape for immune-related disorders.
Supporting Data and Scientific Rationale
The scientific rationale behind both the SIGMA and XPERT trials is firmly rooted in the well-established immunomodulatory and protective properties of immunoglobulins. These complex protein mixtures, primarily composed of IgG antibodies, play a crucial role in the human immune system by neutralizing pathogens, enhancing phagocytosis, and modulating immune responses.
For patients with SID, particularly those undergoing chemotherapy or suffering from hematological malignancies, the body’s ability to produce adequate antibodies is severely compromised. This deficiency leaves them highly susceptible to bacterial infections, which can be life-threatening and significantly impact their quality of life and treatment outcomes. Gamunex-C, as an IVIg therapy, provides a direct infusion of functional antibodies, effectively supplementing the patient’s deficient immune system and offering a vital shield against opportunistic infections. The SIGMA trial’s objective to reduce the SBI rate to less than one per participant per year is a clinically meaningful endpoint that, if achieved, would strongly support the expanded use of Gamunex-C in this vulnerable population.
In the case of CIDP, the autoimmune attack on the myelin sheath is thought to be mediated by specific autoantibodies or by dysregulation of the immune system. Immunoglobulin therapy, particularly IVIg, has demonstrated efficacy in CIDP by modulating these immune processes. Mechanisms proposed include blocking antibody binding to nerve tissues, neutralizing harmful autoantibodies, and interfering with complement-mediated damage. The XPERT trial’s focus on comparing Xembify (SCIg) with Gamunex-C (IVIg) for maintenance therapy is based on the understanding that both routes of administration deliver therapeutic levels of immunoglobulins. The key question is whether the pharmacokinetic profile and clinical efficacy of subcutaneous administration can match that of intravenous administration in maintaining disease control and improving patient well-being. Demonstrating non-inferiority would pave the way for broader adoption of SCIg for CIDP, offering patients a more convenient and potentially less burdensome treatment option.
Official Responses and Future Outlook
Eduardo Herrero, Executive Vice President of Industrial and Scientific Innovation at Grifols Biopharma, expressed enthusiasm regarding the potential impact of these trials. "We’re excited about the potential to provide patients with more immunoglobulin treatment options to help manage their conditions with flexibility and convenience," Herrero stated. "Whether it’s our IVIg or SCIg treatments, Grifols’ Igs are backed by decades of deep expertise on this protein."
This statement underscores Grifols’ strategic vision: to leverage its profound understanding of immunoglobulin proteins to develop and refine therapies that cater to evolving patient needs and preferences. The emphasis on "flexibility and convenience" highlights a patient-centric approach, recognizing that treatment adherence and overall satisfaction are critical components of successful long-term disease management.
The successful completion of the SIGMA and XPERT trials and subsequent regulatory approvals could have significant implications for both patient care and the market landscape of immunoglobulin therapies. For patients with SID, a proven benefit of Gamunex-C in preventing serious infections could lead to improved prognoses and reduced healthcare utilization. For CIDP patients, the potential approval of Xembify as a non-inferior alternative to IVIg would represent a major advancement in treatment accessibility and patient empowerment, allowing for more home-based and less time-consuming administration.
Implications for the Broader Healthcare Ecosystem
The expansion of Grifols’ immunoglobulin portfolio through these Phase III trials has far-reaching implications for the broader healthcare ecosystem.
- Enhanced Patient Access and Choice: By potentially adding new indications for Gamunex-C and establishing Xembify as a viable alternative for CIDP, Grifols is contributing to a more robust therapeutic armamentarium. This increased choice empowers both clinicians and patients to select the most appropriate treatment based on individual circumstances, disease severity, and lifestyle considerations.
- Advancement of Subcutaneous Immunoglobulin Therapy: The XPERT trial’s focus on Xembify’s non-inferiority to IVIg is particularly significant. The successful demonstration of this would further validate and promote the use of SCIg, a modality that offers considerable advantages in terms of patient convenience, reduced healthcare resource utilization (e.g., fewer clinic visits), and potential for improved quality of life. This could encourage further research and development in SCIg therapies across various indications.
- Reinforcing Grifols’ Market Leadership: These pivotal trials reinforce Grifols’ position as a leading innovator in the field of plasma-derived medicines. By consistently investing in research and development and pursuing label expansions, the company aims to maintain its competitive edge and meet the growing global demand for immunoglobulin therapies.
- Economic Impact: Successful label expansions can lead to increased market share for Grifols, contributing to its economic growth and its ability to reinvest in further research and manufacturing capabilities. Furthermore, improved treatment outcomes and reduced complications for patients can translate into significant cost savings for healthcare systems by mitigating hospitalizations and long-term care needs.
- Contribution to Scientific Knowledge: The data generated from the SIGMA and XPERT trials will contribute valuable scientific knowledge to the understanding of immunoglobulin therapy in SID and CIDP. This data will be crucial for informing clinical practice guidelines, future research endeavors, and the development of next-generation immunoglobulin products.
As the SIGMA and XPERT trials progress, the global medical community will be closely watching for the results, which hold the promise of expanding treatment horizons and significantly improving the lives of patients managing complex immune system disorders.
About the Author
